This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Pfizer Mends With Vicuron Buy

"We see the deal is strategically positive and at an acceptable valuation," says Catherine J. Arnold of Credit Suisse First Boston in a research report to clients. Arnold, who has a neutral rating on Pfizer, said the transaction should boost Pfizer's presence in hospitals.

Considering Pfizer's "need for products and its strong financial position, the price is not surprising," says Arnold, who doesn't own shares and whose firm has an investment banking relationship with Pfizer.

"Given Vicuron's two potentially blockbuster products ... plus a development program for novel antibiotics, we view this price as fair," adds Winton Gibbons of William Blair & Co., in a report to clients Thursday. Gibbons doesn't own shares, and his firm doesn't have an investment banking relationship with Pfizer.

Varied Uses

The FDA had been expected to rule on dalbavancin later this month, but the agency recently extended its action date by 90 days to Sept. 21. Gibbons says late-stage clinical trials have shown strong results in fighting complicated skin and soft tissue infections. A midstage clinical trial found the drug worked well in fighting bloodstream infections caused by catheters, Gibbons says.

Dalbavancin belongs to the same class of drugs as vancomycin, one of the most powerful antibiotics on the market that is administered to hospital patients who have dangerous bacterial infections that are resistant to other types of antibiotics. "Dalbavancin has been specifically designed as an improved alternative to vancomycin," Vicuron says.

Anidulafungin has produced positive late stage-clinical trial results for fighting fungal infections that affect the skin or mucous membrane but which also can enter the bloodstream and attack the heart. Test results issued earlier this year showed that Vicuron's drug did a better job than Pfizer's Diflucan.

Vicuron is seeking FDA approval of the drug for fungal infections of the esophagus. The agency is expected to act on Nov. 27.

Pfizer has been working with Vicuron on developing new antibiotics. Pfizer says these experimental pills are being tested to see if they have "improved potency and a broader spectrum of activity than existing classes of compounds." Pfizer is looking at several Vicuron compounds to see if they merit being tested in clinical trials.

2 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,943.81 +28.74 0.17%
S&P 500 1,967.57 +2.89 0.15%
NASDAQ 4,415.49 +19.2860 0.44%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto
Advertising Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs